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Type 2 diabetes mellitus (DM2) is a serious public health burden, and is one of the 
prime causes of morbidity and mortality in patients with cardiovascular diseases (CVD), like 
coronary artery disease (CAD), heart failure (HF), stroke or peripheral artery disease [1–4]. 
However, until recently, DM2 management with tight glycemic control, has not been 
associated with any major improvement in terms of survival in patients with CVD. Thus, the 
recent introduction of a novel class of agents for the treatment of DM2 — sodium-glucose co-
transporter 2 inhibitors (SGLT2i) — has proven to be a breakthrough. These inhibitors 
combine proximal tubule diuretic and osmotic action leading to a reduction in glucose 
reabsorption, and mild natriuretic and diuretic effects. Following up on these unique effects, 
several studies showed that treatment with SGLT2i may not only increase the efficacy of 
standard antidiabetic therapy, but also reduce CVD and heart failure (HF) mortality [5–8].  
Until now, the utilization of SGLT2i in Poland has been relatively limited, which has 
meant there is a lack of experience in their usage, and underutilization in the treatment of 
patients. Herein, a study with this novel class of drugs is reported in a cohort of 52 Polish 
DM2 patients with CVD, including a large proportion of patients with HF, all of whom were 
prescribed SGLT2i. 
A retrospective analysis was performed that included 52 diabetic out- or inpatients, 
who agreed to treatment with SGLT2i between 2017 and 2019. At baseline, all patients 
underwent a detailed diagnostic work-up: clinical evaluation, blood tests (including NT-
proBNP, fasting glucose, HbA1c, cholesterol LDL and creatinine levels), electrocardiogram 
(ECG) and echocardiography. Telephone contact or outpatient visits were carried out in 
December 2019 and January 2020. The investigation conforms to the principles outlined in 
the Declaration of Helsinki.  
All parameters are presented as means ± standard deviation or counts (percentages) 
when appropriate. All variables were tested for normal distribution of data with the Shapiro-
Wilk test. Comparisons of continuous parameters between patients with and without HF were 
conducted with t-tests when normality was confirmed, or otherwise, with the Mann-Whitney 
test; the χ2 test was performed for the comparison of qualitative parameters. All results were 
considered statistically significant when their p-value was < 0.05. The Statistica package, 
version 13.0 (StatSoft, TIBCO Software Inc.), was used for the statistical analysis. 
Out of 52 patients 50 (96%) received empagliflozin and 2 (4%) dapagliflozin. Most 
patients (40; 77%) were also treated with metformin, 15 (29%) received insulin and 10 (19%) 
sulphonylurea. Patients were stratified into those with (36.7%) and those without HF (16.3%) 
(Table 1). Both groups were burdened with a high number of CVD and CVD risk factors. 
Fasting glucose was significantly higher in the HF group; however, HbA1c was similar. 
Understandably, HF patients had larger left ventricles with much worse systolic function. 
Following SGLT2i initiation, tolerance was very good and there were no complaints of any 
immediate side effects.  
After a follow-up of 16.3 ± 23.6 months, 47 (90%) patients were continuing treatment 
with SGLT2i. The main reason for SGLT2i discontinuation was the price of the medication 
(no subsidy in the form of a reimbursement was available). Three (5.8%) patients reported 
benign urinary tract infection (uncomplicated cystitis or urethritis) during the course of 
treatment, which resolved itself without major incident (no prolonged antibiotic therapy or 
hospitalization were required). As for the HF group, their New York Heart Association 
(NYHA) class improved (baseline: 2.3 ± 0.65 vs. follow-up: 2.0 ± 0.67; p = 0.04), patients 
reported sustained weight-loss of 4.5 ± 5.6 kg, and required lower daily furosemide dosage 
(baseline: 56.7 ± 20.7 vs. follow-up: 46.7 ± 53.6 mg/day; p = 0.03). 
Type 2 diabetes mellitus and CVD, especially CAD and HF, independently contribute 
to cardiovascular morbidity [2, 3, 9]. They frequently coexist — DM2 is present in up to 45% 
of HF patients — and HF death is one of the most common causes of death among patients 
with both CVD and DM2 [3, 10]. Numerous studies published in the last decade have 
reported on negligible improvement in terms of mortality rates in patients with DM2 and 
coexisting CVDs. It is only recently that large outcome trials have demonstrated the 
unprecedented efficacy of SGLT2i in the reduction of major cardiovascular events [5, 6]. 
Furthermore, it seems that we are on the verge of a paradigm shift in the management of DM2 
(with and without CVDs). Therefore, the SGLT2i are a class I recommendation for DM2 
patients with high CVD risk in the latest guidelines from the European Society of Cardiology 
2019, especially with poor DM2 control [3].  
Presented herein, are the first Polish results of treatment with SGLT2i. Overall, there 
was a very good uptake of this new therapy; in the present study, the SGLT2i was mostly 
introduced in high-risk patients with CVD which had already been established, of whom a 
large proportion consisted of HF patients. As for side effects, a very small number of urinary 
tract infections (an anticipated and previously reported problem due to glucosuria) occurred 
during the course of treatment (a treatment lasting for more than 2 years for some patients). 
However, it was slightly more prevalent than in other studies presented (1.5% in dapagliflozin 
and 1.7% in empagliflozin analysis) [5, 6]. Moreover, in contrast to those studies there were 
no genital infections observed in the current population. Reassuringly, substantial 
improvements were observed in HF patients in terms of symptoms and physical performance 
(lower NYHA class), sustainable weight reduction, along with a simultaneous reduction in 
furosemide daily dosage.  
Initial experience with a new class of antidiabetic drugs — SGLT2i is very positive 
and shows results similar to those reported in major trials and registries. The sustainable 
benefit in the HF subgroup is of particular importance as these patients are particularly prone 
to complications. As it has recently been announced that the cost of SGLT2i can be 
reimbursed in Poland (with the application of strict criteria for eligibility), there now seems to 
be a ray of hope on the horizon for patients with DM2 and CVDs.     
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Table 1. Detailed characteristics of the study population.  
Parameter Patients with 
HF (n = 36) 
Patients without 
HF (n = 16) 
P 
Age [years] 64.6 ± 9.0 60.4 ± 13.5 0.47 
Male  29 (81%) 10 (63%) 0.32 
Heart rate [bpm] 76.3 ± 11.0 73.2 ± 9.9 0.51 
Atrial hypertension  31 (86%) 14 (88%) 0.89 
Coronary artery disease  27 (75%) 10 (91%) 0.53 
Atrial fibrillation  8 (22%) 6 (38%) 0.15 
Dyslipidemia  31 (86%) 16 (100%) 0.006 
Obesity  18 (58%) 9 (56%) 0.52 
Ejection fraction [%] 38 ± 16 57 ± 8 < 0.001 
LV end-diastolic diameter [mm] 57 ± 10 51 ± 5 0.03 
Fasted glucose [mg/dL] 10.6 ± 4.5 6.7 ± 1.7 < 0.001 
HbA1c [%] 8.8 ± 3.1 6.9 ± 1.6 0.48 
Creatinine [mg/dL] 110 ± 71 83 ± 11 0.03 
Cholesterol LDL [mmol/L] 2.8 ± 1.1 2.7 ± 1.4 0.64 
Metformin  27 (75%) 13 (81%) 0.86 
Insulin  12 (33%) 3 (19%) 0.46 
Sulphonylurea  8 (22%) 2 (12.5%) 0.06 
All data are presented as means ± standard deviation or counts (percentages). LDL — low 
density lipoprotein; LV — left ventricle 
 
